Aspirin is a well-established therapy for the secondary prevention of cardiovascular events. However, its role in the primary prevention of cardiovascular disease is unclear, especially in older people who are at increased risk. In a large clinical trial to determine the risks and benefits of low-dose daily aspirin in healthy older adults without prior cardiovascular events, aspirin did not prolong healthy and independent living (life free of dementia or persistent physical disability). The risk of dying from a variety of causes, including cancer and heart disease, varies and will require additional analysis and additional follow-up by study participants. These initial findings from the ASPirin Elderly Event Reduction (ASPREE) trial, partially supported by the National Institutes of Health, were published online on September 16, 2018 in three articles in The New England Journal of Medicine. Clinical guidelines point to the benefits of aspirin in preventing heart attacks and strokes in people with vascular conditions such as coronary artery disease, "said NIA Director Richard J. Hodes, MD." The concern has been uncertainty about whether aspirin is beneficial for healthy older people without these conditions. This study shows why this type of research is so important, so that we can get a more complete picture of the benefits and risks of aspirin among healthy older people. "
Case Report: Cardiovascular Diseases & Diagnosis
Case Report: Cardiovascular Diseases & Diagnosis
Research Article: Cardiovascular Diseases & Diagnosis
Research Article: Cardiovascular Diseases & Diagnosis
Research Article: Cardiovascular Diseases & Diagnosis
Research Article: Cardiovascular Diseases & Diagnosis
Case Report: Cardiovascular Diseases & Diagnosis
Case Report: Cardiovascular Diseases & Diagnosis
Research Article: Cardiovascular Diseases & Diagnosis
Research Article: Cardiovascular Diseases & Diagnosis
Keynote: Cancer Science & Therapy
Keynote: Cancer Science & Therapy
Scientific Tracks Abstracts: Journal of Health & Medical Informatics
Scientific Tracks Abstracts: Journal of Health & Medical Informatics
Posters-Accepted Abstracts: Journal of Bioengineering & Biomedical Science
Posters-Accepted Abstracts: Journal of Bioengineering & Biomedical Science
Scientific Tracks Abstracts: Journal of Nephrology & Therapeutics
Scientific Tracks Abstracts: Journal of Nephrology & Therapeutics
Scientific Tracks Abstracts: Journal of Nephrology & Therapeutics
Scientific Tracks Abstracts: Journal of Nephrology & Therapeutics
Cardiovascular Diseases & Diagnosis received 427 citations as per Google Scholar report